Page 114 - Drug Class Review

Page 87 of 205
Drug Effectiveness Review Project

placebo 74.0 61.0 11.97 Secondary Outcome Measures: sMMSE; SIB; DAD; ADL; IADL; modified IADL (IADL+); PSMS+; DON-treated patients had a significantly slower decline of measures of daily functioning than placebo-treated patients; differences were +6.83 (P < 0.001) in IADL, +1.32 (P = 0.0015) in Behavioral and neuropsychiatric symptoms, as measured by NPI 12 item, showed significant differences in favor of DON (mean difference = 6.64 at 24 weeks); significant differences in favor of DON were found in depression/dysphoria (P = 0.0166), anxiety (P = 0.0128), and There

Alzheimer classification: Moderate-Severe

Groups similar at baseline: Yes

Health Outcome Measures:

donepezil 73.3 61.1 11.72 Primary Outcome Measures: CIBIC-plus NPI; FRS; CSS; Caregiver SF-36; CAUST Timing of assessments: Baseline and weeks 4, 8, 12, 18 and 24 PSMS, and 8.24 in DAD (P < 0.0001) at week 24 apathy/indifference (P = 0.0018) Intermediate Outcome Measures: improved or no decline (P < 0.0001)*

• • • •

Final Report Update 1 Authors: Feldman et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Other germane population qualities: Mean baseline sMMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs